- Theratechnologies press release ( NASDAQ: THTX ): Q3 Revenue of $20.81M (+16.6% Y/Y) beats by $0.07M .
- Given the increase in revenue and the smaller increase in expenses in the Q3 2022, net loss improved to $7.55M from $9.51M in the Q3 2021.
- North American Revenue Growth of 19%
-
TH1902 Phase 1 basket trial proceeding as planned.
-
2022 Guidance: Revenue guidance is on track to be in the range of $79-$82M vs. consensus of $79.49M , or growth of the commercial portfolio to be in the range of 13% and 17%, as compared to the 2021 fiscal year.
-
Shares +0.48% PM.
For further details see:
Theratechnologies reports Q3 results, FY22 guidance on track